Royal Society seeking 'white knight'

An urgent plea has gone out from Britain's Royal Society, calling for a ?white knight? to buy some notes written by Robert Hooke in the late 1600s and make them available to researchers. Hooke worked with Robert Boyle, coined the term 'cell' and helped rebuild London, among other things. He was an early secretary of the Royal Society and the papers in question are annotated and draft minutes from early meetings. Given all of which, it seems a shame that the Royal Society isn't in a financial

Written byStephen Pincock
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
An urgent plea has gone out from Britain's Royal Society, calling for a ?white knight? to buy some notes written by Robert Hooke in the late 1600s and make them available to researchers. Hooke worked with Robert Boyle, coined the term 'cell' and helped rebuild London, among other things. He was an early secretary of the Royal Society and the papers in question are annotated and draft minutes from early meetings. Given all of which, it seems a shame that the Royal Society isn't in a financial position to buy the notes itself. But that apparently is the case. On February 9 the Society's president, Martin Rees, issued a press release calling for someone to buy the collection so they aren't lost to 'researchers on the early history of the Royal Society, and its role in the development of modern science.' There have been a few high profile cases of important historical documents being bought and made available by folks in recent times. Bill Gates purchased Leonardo's Codex Leicester back in the 1990s and had it displayed in the Seattle Art Museum, while Craig Venter last year snapped up a collection of early genetics documents which he plans to include in an archive that will be available to reserachers. Perhaps the Royal Society is hoping something similar will happen with the Hooke notes. As Rees said in the press release, 'It is a great pity that the Royal Society cannot itself afford to purchase them so that they could be restored to our collection of documents, from which they were removed at some point during our early history.' Hint, hint. Either way, we'll find out when they go under the hammer on March 28.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies